Functional analysis of human tissue kallikrein in transgenic mouse models

Hypertension

Volumn 27, Issue 3 II, 1996, Pages 491-494

  Chao, Julie ^a   Chao, Lee ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

aprotinin; kallikrein; kallikrein binding protein; mice, transgenic; somatic gene delivery

Indexed keywords

APROTININ; KALLIKREIN; KALLIKREIN BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD PRESSURE REGULATION; GENE TARGETING; HUMAN; HYPERTENSION; HYPOTENSION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0029868140     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.27.3.491     Document Type: Article

References (29)

1. Margolius HS. Tissue kallikreins and kinins: regulation and roles in hypertensive and diabetic diseases. Annu Rev Pharmacol Toxicol. 1989;29:343-364.
2. Muller-Esterl W. Kininogens, kinins and kinships. Thromb Haemost. 1989;61:2-6.
3. Clements JA. The glandular kallikrein family of enzymes: tissue-specific expression and hormonal regulation. Endocr Rev. 1989;10: 393-429.
4. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 1992;44:1-80.
5. Margolius HS, Horwitz D, Pisano JJ, Keiser HR. Urinary kallikrein excretion in hypertensive man: relationships to sodium intake and sodium-retaining steroids. Circ Res. 1974;35:820-825.
6. Zinner SH, Margolius HS, Rosner B, Kass EH. Stability of blood pressure rank and urinary kallikrein concentration in childhood: an eight-year follow-up. Circulation. 1978;58:908-915.
7. Berry TD, Hasstedt SJ, Hunt SC, Wu LL, Smith JB, Ash KO. A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension. 1989;13:3-8.
8. Margolius HS, Geller R, De Jong W, Pisano JJ, Sjoerdsma A. Altered urinary kallikrein excretion in rats with hypertension. Circ Res. 1972;30:358-362.
9. Ader JL, Pollock DM, Butterfield MI, Arendshorst WJ. Abnormalities in kallikrein excretion in spontaneously hypertensive rats. Am J Physiol. 1985;248:F396-F403.
10. Woodley-Miller C, Chao J, Chao L. Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kailikrein probes. J Hypertens. 1989;7:865-871.
11. Pravenec M, Ken V, Kunes J, Scicli G, Carretero OA, Simonet LI. Cosegregation of blood pressure with a kailikrein gene family polymorphism. Hypertension. 1991;17:242-246.
12. Chao J, Chai KX, Chen LM, Xiong W, Chao S, Woodley-Miller C, Chao L. Tissue kallikrein-binding protein is a serpin, I: purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J Biol Chem. 1990;265:16394-16401.
13. Zhou GX, Chao L, Chao J. Kallistatin: a novel human tissue kailikrein inhibitor. Purification, characterization, and reactive center sequence. J Biol Chem. 1992;267:25873-25880.
14. Chai K, Chen LM, Chao J, Chao L. Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution and expression in E. coli. J Biol Chem. 1993;268:24498-24505.
15. Chai KX, Chao J, Chao L. Molecular cloning and sequence analysis of the mouse kallikrein-binding protein gene. Biochim Biophys Acta. 1991;1129:127-130.
16. Serveau C, Toreau T, Zhou GX, Chao J, Gauthier F. Inhibition of rat tissue kallikrein gene family members by rat kallikrein-binding protein and a1-proteinase inhibitor. FEBS Lett. 1992;309:405-408.
17. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature. 1990; 344:541-544.
18. Fukamizu A, Sugimura K, Takimoto E, Sugiyama F, Seo MS, Takahashi S, Hatae T, Kajiwara N, Yagami K, Murakami K. Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem. 1993;268:11617-11621.
19. Ohkubo H, Kawakami H, Kakehi Y. Generation of transgenic mice with elevated blood pressure by introduction of the rat renin and angiotensinogen genes. Proc Natl Acad Sci U S A. 1990;87: 5153-5157.
20. Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fusion gene. Hypertension. 1990;16:301-307.
21. Wang J, Xiong W, Yang Z, Davis T, Dewey MJ, Chao J, Chao L. Human tissue kallikrein induces hypotension in transgenic mice. Hypertension. 1994;23:236-243.
22. Xiong W, Wang J, Chao J, Chao L. Regulatory elements and tissue-specific expression of human tissue kallikrein in transgenic mice. FASEB J. 1993;7:A1222. Abstract.
23. Overlack A, Stumpe KO, Kolloch R, Ressel C, Krueck F. Antihypertensive effect of orally administered glandular kallikrein in essential hypertension: results of double blind study. Hypertension. 1981;3(suppl I):I-18-I-21.
24. Ogawa K, Ito T, Ban M, Mochizuki M, Satake T. Effects of orally administered glandular kallikrein on urinary kallikrein and prostaglandin excretion, plasma immunoreactive prostanoids and platelet aggregation in essential hypertension. Klin Wochenschr. 1985;63: 332-336.
25. Bellini C, Ferri C, Piccoli A, Corlomagno A, Di Francesco L, Bonavita MS, Santucci A, Balsano F. The influence of salt-sensitivity on the blood pressure response to exogenous kallikrein in essential hypertensive patients. Nephron. 1993;65:28-35.
26. Chao J, Chao L. Biochemistry, regulation and potential function of kallistatin. Biol Chem Hoppe Seyler. 1995;376:705-713.
27. Xiong W, Tong C, Zhou G, Chao L, Chao J. In vivo catabolism of human kallikrein-binding protein and its complex with tissue kallikrein. J Lab Clin Med. 1992;119:514-521.
28. Ma J, Yang Z, Chao J, Chao L. Intramuscular delivery of rat kallikrein-binding protein gene reverses hypotension in transgenic mice expressing human tissue kallikrein. J Biol Chem. 1995;270: 451-455.
29. Wight DC, Wagner TE. Transgenic mice: a decade of progress in technology and research. Mutat Res. 1994;307:429-440.